Literature DB >> 3627361

Characterization of [3H]cholecystokinin octapeptide binding to mouse brain synaptosomes: effects of neuroleptics.

Y Hama, M Ebadi.   

Abstract

The presence of high concentrations of both dopamine and cholecystokinin (CCK) in the striatum and in various limbic structures suggests that the CCK may not only influence dopaminergic transmission, but it also may be relevant to the psychopathology of schizophrenia and to the therapeutic effects of neuroleptics. By using a synaptosomal fraction isolated from the mouse cerebral cortex and [propionyl-3H]CCK8-sulphate ([3H]CCK8S) as a ligand, a single binding site for [3H]CCK8 with a KD value of 1.04 nM and a Bmax value of 42.9 fmol/mg protein was identified. The competitive inhibition of [3H]CCK8S binding by related peptides produced an order of potency of CCK8-sulphated (IC50 = 5.4 nM) greater than CCK8-unsulfated (IC50 = 40 nM) and greater than CCK4 (IC50 = 125 nM). The regional distribution of [3H]CCK8S binding in the mouse brain was highest in the olfactory bulb (34.3 +/- 5.6 fmol/mg protein) greater than cerebral cortex greater than cerebellum greater than olfactory tubercle greater than striatum greater than pons-medulla greater than mid brain greater than hippocampus greater than hypothalamus (12.4 +/- 2.1 fmol/mg protein). The repeated administration of haloperidol (2.5 mg/kg/tid) increased the binding of [3H]CCK8S in cerebral cortex from 31.8 +/- 1.7 to 38.9 +/- 5.2 fmol/mg protein. The varied distribution of CCK8S receptors may signify nonuniform functions for the octapeptide in the brain.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3627361     DOI: 10.1007/BF00970529

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  43 in total

1.  Modification of the C-terminal octapeptide of cholecystokinin with a high-specific-activity iodinated imidoester: preparation, characterization, and binding to isolated pancreatic acinar cells.

Authors:  M Praissman; R S Izzo; J M Berkowitz
Journal:  Anal Biochem       Date:  1982-03-15       Impact factor: 3.365

2.  A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing.

Authors:  T Hökfelt; L Skirboll; J F Rehfeld; M Goldstein; K Markey; O Dann
Journal:  Neuroscience       Date:  1980       Impact factor: 3.590

3.  Effect of cholecystokinin of the activity of midbrain dopaminergic neurons.

Authors:  B S Bunney; A A Grace; D W Hommer; L R Skirboll
Journal:  Adv Biochem Psychopharmacol       Date:  1982

4.  Gastrointestinal peptides in the brain.

Authors:  E Straus; R S Yalow
Journal:  Fed Proc       Date:  1979-08

5.  The nullification by diazepam of haloperidol-induced increases in the level of striatal dopamine but not in the activity of glutamic acid decarboxylase.

Authors:  Y Hama; M Ebadi
Journal:  Neuropharmacology       Date:  1986-11       Impact factor: 5.250

6.  Modulation of [3H]-dopamine binding by cholecystokinin octapeptide (CCK-8).

Authors:  R B Murphy; D I Schuster
Journal:  Peptides       Date:  1982 May-Jun       Impact factor: 3.750

7.  Localization and molecular heterogeneity of cholecystokinin in the central and peripheral nervous system.

Authors:  L I Larsson; J F Rehfeld
Journal:  Brain Res       Date:  1979-04-13       Impact factor: 3.252

Review 8.  Functions of the frontal cortex of the rat: a comparative review.

Authors:  B Kolb
Journal:  Brain Res       Date:  1984-11       Impact factor: 3.252

9.  Antistereotypic effects of cholecystokinin octapeptide (CCK-8), ceruletide and related peptides on apomorphine-induced gnawing in sensitized mice.

Authors:  G Zetler
Journal:  Neuropharmacology       Date:  1985-03       Impact factor: 5.250

10.  Characterization of receptors for cholecystokinin and related peptides in mouse cerebral cortex.

Authors:  A Saito; I D Goldfine; J A Williams
Journal:  J Neurochem       Date:  1981-08       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.